The Psoriasis SCID Mouse Model: A Tool for Drug Discovery?

  • W. -H. Boehncke
Part of the Ernst Schering Research Foundation Workshop book series (SCHERING FOUND, volume 50)


SCID Mouse Severe Combine Immunodeficiency Clobetasol Propionate Lesional Psoriatic Skin SCID Mouse Model 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Asadullah K, Sterry W, Stephanek K, Jasulaitis D, Leupold M, Audrich H, Volk HD, Docke WD (1998) IL-10 is a key cytokine in psoriasis: proof of principle by IL-10 therapy: a new therapeutic approach. J Clin Invest 101:783–794PubMedCrossRefGoogle Scholar
  2. Bangha E, Eisner P (1996) Evaluation of topical antipsoriatic treatment by chromametry, visiometry and 20-MHz ultrasound in the psoriasis plaque test. Skin Pharmacol 9:298–306PubMedCrossRefGoogle Scholar
  3. Beamer WG, Pelsue SC, Shultz LD, Sundberg JP, Barker JE (1995) The flaky skin (fsn) mutation in mice: map location and description of the anemia. Blood 86:3220–3226PubMedGoogle Scholar
  4. Boehncke W-H (1997) Animal models for psoriasis. Hautarzt 48:707–713PubMedCrossRefGoogle Scholar
  5. Boehncke W-H (1999) The SCID-hu xenogeneic transplantation model: complex but telling. Arch Dermatol Res 291:367–373PubMedCrossRefGoogle Scholar
  6. Boehncke W-H (2003) Managing psoriasis with immunomodulatory drugs: the next generation. Br Med J 327:634–635CrossRefGoogle Scholar
  7. Boehncke W-H, Schön MP (2003) Interfering with leukocyte rolling — a promising therapeutic approach in inflammatory skin disorders? Trends Pharmacol Sci 24:49–52PubMedCrossRefGoogle Scholar
  8. Boehncke W-H, Sterry W, Hainzl A, Scheffold W, Kaufmann R (1994) Psoriasiform architecture of murine epidermis overlying human psoriatic dermis transplanted on SCID mice. Arch Dermatol Res 286:325–330PubMedCrossRefGoogle Scholar
  9. Boehncke W-H, Dressel D, Zollner TM, Kaufmann R (1996) Pulling the trigger on psoriasis. Nature 379:777PubMedCrossRefGoogle Scholar
  10. Boehncke W-H, Kock M, Hardt-Weinelt K, Wolter M, Kaufmann R (1999) The SCID-hu xenogeneic transplantation model allows screening of anti-psoriatic drugs. Arch Dermatol Res 291:104–106PubMedCrossRefGoogle Scholar
  11. Bosma GC, Custer RP, Bosma MJ (1983) A severe combined immunodeficiency mutation in mouse. Nature 301:527–530PubMedCrossRefGoogle Scholar
  12. Carroll JM, Romero MR, Watt FM (1995) Suprabasal integrin expression in the epidermis of transgenic mice results in developmental defects and a phenotype resembling psoriasis. Cell 83:957–968PubMedCrossRefGoogle Scholar
  13. Dam TN, Kang S, Nickoloff BJ, Voorhees JJ (1999) 1α,25-dihydroxycholecalciferol and cyclosporine suppress induction and promote resolution of psoriasis in human skin grafts transplanted on to SCID mice. J Invest Dermatol 113:1082–1089PubMedCrossRefGoogle Scholar
  14. Dominey AM, Wang X-J, King LE, Nanney LB, Gagne TA, Sellheyer K, Bundman DS, Longley MA, Rothnagel JA, Greenhalgh DA, Roop DR (1993) Targeted overexpression of transforming growth factor alpha in the epidermis of transgenic mice elicits hyperplasia, hyperkeratosis, and spontaneous squamous papillomas. Cell Growth Diff 4:1071–1082PubMedGoogle Scholar
  15. Dunstan RW, Rosser ER (1986) Does a condition like human pityriasis rosea occur in pigs? Am J Dermatopathol 8:86–89PubMedCrossRefGoogle Scholar
  16. Elliott PJ, Zollner TM, Boehncke W-H (2003) Proteasome inhibition: a new anti-inflammatory strategy. J Mol Med 81:235–245PubMedGoogle Scholar
  17. Ellis CN, Varani J, Fisher GJ, Zeigler ME, Pershadsingh HA, Benson SC, Chi Y, Kurtz TW (2000) Troglitazone improves psoriasis and normalizes models of proliferative skin disease. Arch Dermatol 136:609–616PubMedCrossRefGoogle Scholar
  18. Foulop GM, Phillips RA (1990) The scid mutation in mice causes a general defect in DNA repair. Nature 347:479–482CrossRefGoogle Scholar
  19. Gilhar A, Ullmann Y, Kerner H, Asy B, Shalaginov R, Serafimovich S, Kalish RS (2002) Psoriasis is mediated by a cutaneous defect triggered by activated immunocytes: induction of psoriasis by cells with natural killer receptors. J Invest Dermatol 119:384–391PubMedCrossRefGoogle Scholar
  20. Gottlieb AB, Miller B, Lowe N, Shapiro W, Hudson C, Bright R, Ling I, Magee A, McCall CO, Rist T, Dummer W, Walicke P, Bauer RJ, White M, Garovoy M (2003) Subcutaneously administered efalizumab (anti-CD 11a) improves signs and symptoms of moderate to severe plaque psoriasis. J Cutan Med Surg (in press)Google Scholar
  21. Haftek M, Ortonne J-P, Staquet M-J, Viac J, Thivolet J (1981) Normal and psoriatic human skin grafts on “nude” mice: morphological and immuno-histochemical studies. J Invest Dermatol 76:48–52PubMedCrossRefGoogle Scholar
  22. Hammer RE, Maika SD, Richardson JA, Tang J-P, Taurog JD (1990) Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human β2m: an animal model of HLA-B27-associated human disorders. Cell 63:1099–1112PubMedCrossRefGoogle Scholar
  23. Henry RR (1997) Thiazolidinediones. Endocrinol Metab Clin North Am 26:553–573PubMedCrossRefGoogle Scholar
  24. Henseler T, Christophers E (1985) Psoriasis of early and late onset: characterization of two types of psoriasis. J Am Acad Dermatol 13:450–456PubMedCrossRefGoogle Scholar
  25. Herz U, Daser A, Renz H (1997) The humanized (Hu-PBMC) SCID mouse as an in vivo model for human IgE production and allergic inflammation of the skin. Int Arch Allergy Immunol 113:150–152PubMedCrossRefGoogle Scholar
  26. Jayo MJ, Zanolli MD, Jayo JM (1988) Psoriatic plaques in macaca fascicularis. Vet Pathol 25:282–285PubMedCrossRefGoogle Scholar
  27. Kaufmann R, Mielke V, Hainzl A, Klein CE, Reimann J, Sterry W (1993) Cellular and molecular composition of human skin xenografts on SCID-mice. Exp Dermatol 2:209–216PubMedCrossRefGoogle Scholar
  28. Krueger GG, Manning DD, Malouf J, Ogden B (1975) Long-term maintenance of psoriatic human skin on congenitally athymic (nude) mice. J Invest Dermatol 64:307–312PubMedCrossRefGoogle Scholar
  29. Lowe NJ, Breeding J, Kean C, Cohn ML (1981) Psoriasiform dermatosis in a rhesus monkey. J Invest Dermatol 76:141–143PubMedCrossRefGoogle Scholar
  30. Mason KV, Halliwell RE, McDougal BJ (1996) Characterization of lichenoid-psoriasiform dermatosis of springer spaniels. J Am Vet Med Assoc 189:897–901Google Scholar
  31. Morimoto S, Yoshikawa K, Kozuka T, Kitano Y, Imanaka S, Fukuo K, Koh E, Kumahara Y (1986) An open study of vitamin D3 treatment in psoriasis vulgaris. Br J Dermatol 115:421–429PubMedCrossRefGoogle Scholar
  32. Nickoloff BJ (2000) The search for pathogenic T cells and the genetic basis of psoriasis using a severe combined immunodeficiency mouse model. Cutis 65:110–114PubMedGoogle Scholar
  33. Petzelbauer P, Gröger M, Kunstfeld R, Petzelbauer E, Wolff K (1996) Human delayed-type hypersensitivity reaction in a SCID mouse engrafted with human T cells and autologous skin. J Invest Dermatol 107:576–581PubMedCrossRefGoogle Scholar
  34. Reed ND, Manning DD (1973) Long term maintenance of normal human skin on congenitally athymic (nude) mice. Proc Soc Exp Biol Med 143:350–353PubMedGoogle Scholar
  35. Roth DB, Menetski JP, Nakajima PB, Bosma MJ, Gellert M (1992) V(D)J recombination: broken DNA molecules with covalently sealed (hairpin) coding ends in scid mouse thymocytes. Cell 70:983–991PubMedCrossRefGoogle Scholar
  36. Schön M, Behmenburg C, Denzer D, Schön MP (2001) Pathogenic function of IL-1β in psoriasiform lesions of flaky skin (fsn/fsn) mice. Clin Exp Immunol 123:505–510PubMedCrossRefGoogle Scholar
  37. Schön MP, Krahn T, Schön M, Rodriguez M-L, Antonicek H, Schultz JE, Ludwig RJ, Zollner TM, Bischoff E, Bremm K-D, Schramm M, Henninger K, Kaufmann R, Gollnick HPM, Parker CM, Boehncke W-H (2002) Efomycine M, a new specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation. Nature Med 8:366–372PubMedCrossRefGoogle Scholar
  38. Schuler W, Weiler IJ, Schuler A, Phillips RA, Rosenberg N, Mak TW, Kearney JF, Perry RP, Bosma MJ (1986) Rearrangement of antigen receptor genes is defective in mice with severe combined immunodeficiency. Cell 46:963–972PubMedCrossRefGoogle Scholar
  39. Sellheyer K (1995) Transgenic animals as models for skin diseases. Hautarzt 46:755–761PubMedCrossRefGoogle Scholar
  40. Spiegelman BM (1998) PPAR-α: adipogenic regulator and thiazolidinedione receptor. Diabetes 47:507–514PubMedCrossRefGoogle Scholar
  41. Sundberg JP, Boggess D, Sundberg BA, Beamer WG, Shultz LD (1993) Epidermal dendritic cell populations in the flaky skin mutant mouse. Immunol Invest 22:389–401PubMedCrossRefGoogle Scholar
  42. Vassar R, Fuchs E (1991) Transgenic mice provide new insights into the role of TGF-alpha during epidermal development and differentiation. Genes Dev 5:714–727PubMedCrossRefGoogle Scholar
  43. Wilson JB, Weinberg W, Johnson R, Yuspa S, Levine AJ (1990) Expression of the BNLF-1 oncogene of Epstein-Barr virus in the skin of transgenic mice induces hyperplasia and aberrant expression of keratin 6. Cell 61:1315–1327PubMedCrossRefGoogle Scholar
  44. Wong RL, Winslow CM, Cooper KD (1993) The mechanisms of action of cyclosporine A in the treatment of psoriasis. Immunol Today 14:69–74PubMedCrossRefGoogle Scholar
  45. Yan H-C, Delisser HM, Pilewski JM, Barone KM, Szklut PJ, Chang X-J, Ahern TJ, Langer-Safer P, Albelda SM (1994) Leukocyte recruitment into human skin transplanted onto severe combined immunodeficiency mice induced by TNF-α is dependent on E-selectin. J Immunol 152: 3053–3063PubMedGoogle Scholar
  46. Ziegler M, Chi Y, Tumas DB, Bodary S, Tang H, Varani J (2001) Anti-CD11a ameliorates disease in the human psoriatic skin-SCID mouse transplant model: comparison of antibody to CD11a with cyclosporine A and clobetasol propionate. Lab Invest 81:1253–1261CrossRefGoogle Scholar
  47. Zillikens D, Schmidt E, Reimer S, Chimanovitch I, Hardt-Weinelt K, Rose C, Bröcker E-B, Koch M, Boehncke W-H (2001) Antibodies to desmoglein 1 and 3 but not to BP180 induce blisters in human skin grafted onto SCID mice. J Pathol 193:117–124PubMedCrossRefGoogle Scholar
  48. Zollner TM, Podda M, Pien C, Elliott PJ, Kaufmann R, Boehncke W-H (2002) Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model. J Clin Invest 109:671–679PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Authors and Affiliations

  • W. -H. Boehncke
    • 1
  1. 1.Department of DermatologyUniversity of Frankfurt Medical SchoolFrankfurtGermany

Personalised recommendations